Evidence mapPaperPMID 40348023Full record

ReviewAntiviral research2025

Exploiting host kinases to combat dengue virus infection and disease.

Natasha M Bourgeois, Ling Wei, Alexis Kaushansky, John D Aitchison

Abstract readReview
In one paragraph

Review in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Natasha M BourgeoisCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98101, United States; Department of Global Health, University of Washington, Seattle, WA, 98195, United States.
Ling WeiCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98101, United States.
Alexis KaushanskyCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98101, United States; Department of Global Health, University of Washington, Seattle, WA, 98195, United States; Department of Pediatrics, University of Washington, Seattle, WA, 98195, United States. Electronic address: alexis.kaushansky@seattlechildrens.org.
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98101, United States; Department of Pediatrics, University of Washington, Seattle, WA, 98195, United States; Department of Biochemistry, University of Washington, Seattle, WA, 98195, United States. Electronic address: john.aitchison@seattlechildrens.org.

Funding

DISEASES OF PUBLIC HEALTH IMPORTANCET32AI007509 · UNIVERSITY OF WASHINGTON · 1997 to 2005
$1.2M
Perturbations of host cell signaling by a complex hepatotropic pathogenR01AI177257 · SEATTLE CHILDREN'S HOSPITAL · 2025 to 2025
$663k
NIAID NIH HHS R01 AI177257NIAID NIH HHS T32 AI007509
6 · The paper itself

Abstract

The burden of dengue on human health has dramatically increased in recent years, underscoring the urgent need for effective therapeutic interventions. Despite decades of research since the discovery of the dengue virus, no specific antiviral treatments are available and strategies to reliably prevent severe disease remain limited. Direct-acting antivirals against dengue are under active investigation but have shown limited efficacy to date. An underappreciated Achille's heal of the virus is its dependence on host factors for infection and pathogenesis, each of which presents a potential avenue for therapeutic intervention. We and others have demonstrated that dengue virus relies on multiple host kinases, some of which are already targeted by clinically approved inhibitors. These offer drug repurposing opportunities for host-directed dengue treatment. Here, we summarize findings on the role of kinases in dengue infection and disease and highlight potential kinase targets for the development of innovative host-directed therapeutics.

Indexed as

Antiviral AgentsDengueDengue VirusHost-Pathogen InteractionsPhosphotransferasesProtein KinasesAnimalsDrug RepositioningHumansProtein Kinase InhibitorsAntiviral AgentsPhosphotransferasesProtein Kinase InhibitorsProtein KinasesDengue virusFlavivirusHost-targeted antiviralsKinase inhibitorsKinase signalingNeglected tropical disease

Identifiers

PMID40348023
PMCPMC12245208

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.